$ARTL
ARTELO BIOSCIENCES, INC. Stock $artl

$artl Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000164033423000509 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.057M	$1.750M	$5.963M
YoY Change	-28.68%	36.83%	184.22%
% of Gross Profit
Research & Development	$1.235M	$1.726M	$4.324M
YoY Change	166.16%	35.59%	52.31%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.292M	$3.476M	$10.29M
YoY Change	17.78%	36.21%	38.25%
Operating Profit	-$2.292M		-$10.29M
YoY Change	17.78%		38.25%
Interest Expense	$124.0K	$137.0K	$5.000K
YoY Change	-752.63%	4466.67%	-16.67%
% of Operating Profit
Other Income/Expense, Net	$124.0K		$204.0K
YoY Change	-752.63%		5000.0%
Pretax Income	-$2.168M	-$3.339M	-$10.08M
YoY Change	10.33%	31.04%	149.89%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.168M	-$3.339M	-$10.08M
YoY Change	10.33%	31.04%	35.58%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.76	-$1.18	-$3.56
COMMON SHARES
Basic Shares Outstanding	2.856M shares	2.856M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.916M	$8.383M	$17.53M
YoY Change	-67.85%	-65.23%	-27.29%
Cash & Equivalents	$6.916M	$6.888M	$6.888M
Short-Term Investments	$0.00	$1.495M	$10.65M
Other Short-Term Assets	$903.0K	$789.0K	$789.0K
YoY Change	-16.23%	53.5%	59.07%
Inventory
Prepaid Expenses	$903.0K	$789.0K
Receivables
Other Receivables
Total Short-Term Assets	$16.39M	$18.32M	$18.32M
YoY Change	-33.36%	-25.55%	-25.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$50.00K	$60.00K	$60.00K
YoY Change	-31.51%	-27.71%	-25.93%
Goodwill
YoY Change
Intangibles	$2.039M	$2.039M
YoY Change	0.0%	0.0%
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets	$3.000K	$3.000K	$3.000K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$2.092M	$2.102M	$2.102M
YoY Change	-1.09%	-42.28%	-42.28%
TOTAL ASSETS
Total Short-Term Assets	$16.39M	$18.32M	$18.32M
Total Long-Term Assets	$2.092M	$2.102M	$2.102M
Total Assets	$18.48M	$20.42M	$20.42M
YoY Change	-30.8%	-27.71%	-27.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$701.0K	$905.0K	$905.0K
YoY Change	-12.38%	53.39%	-7.18%
Accrued Expenses	$37.00K	$40.00K	$40.00K
YoY Change	15.63%	29.03%	29.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$825.0K	$998.0K	$998.0K
YoY Change	-5.71%	-2.82%	-2.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$15.00K	$23.00K	$23.00K
YoY Change	-69.39%	-61.02%	-59.65%
Total Long-Term Liabilities	$15.00K	$23.00K	$23.00K
YoY Change	-69.39%	-61.02%	-59.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$825.0K	$998.0K	$998.0K
Total Long-Term Liabilities	$15.00K	$23.00K	$23.00K
Total Liabilities	$840.0K	$1.021M	$1.021M
YoY Change	-9.09%	-5.81%	-5.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$33.19M	-$31.02M
YoY Change	44.91%	48.16%
Common Stock	$3.000K	$3.000K
YoY Change	-92.86%	-92.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.64M	$19.40M	$19.40M
YoY Change
Total Liabilities & Shareholders Equity	$18.48M	$20.42M	$20.42M
YoY Change	-30.8%	-27.71%	-27.71%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.168M	-$3.339M	-$10.08M
YoY Change	10.33%	31.04%	35.58%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$2.186M	-$2.293M	-$8.008M
YoY Change	6.48%	19.06%	30.4%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$2.199M	$1.796M	$2.958M
YoY Change	755.64%	-120.23%	-129.48%
Cash From Investing Activities	$2.199M	$1.796M	$2.958M
YoY Change	755.64%	-120.23%	-186.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	134.0K	$0.00
YoY Change		-99.27%	-100.0%
NET CHANGE
Cash From Operating Activities	-$2.186M	-2.293M	-$8.008M
Cash From Investing Activities	$2.199M	1.796M	$2.958M
Cash From Financing Activities	$0.00	134.0K	$0.00
Net Change In Cash	$28.00K	-363.0K	-$5.274M
YoY Change	-101.55%	-104.87%	-216.37%
FREE CASH FLOW
Cash From Operating Activities	-$2.186M	-$2.293M	-$8.008M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001621221
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	416667	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2855688	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2820068	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1635109	shares
CY2020	artl	Share Based Expenses ShareBasedExpenses	381000	usd
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	6250000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021	artl	Number Of Warrant Granted NumberOfWarrantGranted	10120000	shares
CY2022Q4	artl	Intrinsic Value Of The Warrants IntrinsicValueOfTheWarrants	0	usd
CY2021Q4	artl	Intrinsic Value Of The Warrants IntrinsicValueOfTheWarrants	0	usd
CY2021Q3	artl	Intrinsic Value Of The Warrants IntrinsicValueOfTheWarrants	338	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	74000000	shares
CY2020	artl	Common Stock Shares Issued For Cash CommonStockSharesIssuedForCash	1978000	usd
	artl	Common Stock Shares Issued For Cash CommonStockSharesIssuedForCash	6578000	usd
CY2022	artl	Common Stock Shares Issued For Cash CommonStockSharesIssuedForCash	18262000	usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38951
CY2022	dei	Entity Registrant Name EntityRegistrantName	Artelo Biosciences, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-1220924
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	505 Lomas Santa Fe
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 160
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Solana Beach
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Country EntityAddressCountry	US
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92075
CY2022	dei	City Area Code CityAreaCode	858
CY2022	dei	Local Phone Number LocalPhoneNumber	925-7049
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	ARTL
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	13685251	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2855688	shares
CY2022	dei	Auditor Firm AuditorFirmId	206
CY2022	dei	Auditor Name AuditorName	MaloneBailey, LLP
CY2022	dei	Auditor Location AuditorLocation	Houston
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6888000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12162000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6629000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	9150000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	11951000	usd
CY2021Q3	us-gaap	Marketable Securities MarketableSecurities	3436000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	1502000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1495000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	789000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	496000	usd
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	252000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	18322000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	24609000	usd
CY2021Q3	us-gaap	Assets Current AssetsCurrent	10317000	usd
CY2021Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	1521000	usd
CY2021Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	0	usd
CY2022Q4	artl	Available For Sale Securities Non Currents AvailableForSaleSecuritiesNonCurrents	0	usd
CY2021Q4	artl	Available For Sale Securities Non Currents AvailableForSaleSecuritiesNonCurrents	1519000	usd
CY2021Q3	artl	Available For Sale Securities Non Currents AvailableForSaleSecuritiesNonCurrents	0	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	60000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	81000	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	90000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2039000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2039000	usd
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2039000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3000	usd
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	189000	usd
CY2022Q4	us-gaap	Assets Assets	20424000	usd
CY2021Q4	us-gaap	Assets Assets	28251000	usd
CY2021Q3	us-gaap	Assets Assets	12635000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	905000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	975000	usd
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	471000	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	53000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	21000	usd
CY2021Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	27000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	40000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	31000	usd
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	28000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	998000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1027000	usd
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	526000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57000	usd
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	67000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1021000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1084000	usd
CY2021Q3	us-gaap	Liabilities Liabilities	593000	usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	416667	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2855688	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2820068	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1635109	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	50675000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	48120000	usd
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	28925000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31021000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20938000	usd
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16903000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-254000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-18000	usd
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	18000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	19403000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	27167000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	12042000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20424000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28251000	usd
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12635000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5963000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2098000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4602000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4324000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1944000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2839000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	10287000	usd
	us-gaap	Operating Expenses OperatingExpenses	4042000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	7441000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10287000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4042000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-7441000	usd
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	2000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	1000	usd
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	2000	usd
CY2022	us-gaap	Interest Expense InterestExpense	5000	usd
	us-gaap	Interest Expense InterestExpense	0	usd
CY2021	us-gaap	Interest Expense InterestExpense	0	usd
CY2022	artl	Net Change In Fair Value Of Trading Marketable Securities NetChangeInFairValueOfTradingMarketableSecurities	207000	usd
	artl	Net Change In Fair Value Of Trading Marketable Securities NetChangeInFairValueOfTradingMarketableSecurities	6000	usd
CY2021	artl	Net Change In Fair Value Of Trading Marketable Securities NetChangeInFairValueOfTradingMarketableSecurities	2000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	204000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10083000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4035000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7437000	usd
CY2022	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	24000	usd
	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	5000	usd
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-212000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-31000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-46000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-236000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-36000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-46000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10319000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4071000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7483000	usd
CY2022	artl	Earnings Per Share Basics And Diluted EarningsPerShareBasicsAndDiluted	-3.56
	artl	Earnings Per Share Basics And Diluted EarningsPerShareBasicsAndDiluted	-1.81
CY2021	artl	Earnings Per Share Basics And Diluted EarningsPerShareBasicsAndDiluted	-5.97
CY2022	artl	Weighted Average Number Of Share Outstanding Basics And Diluted WeightedAverageNumberOfShareOutstandingBasicsAndDiluted	2833000	shares
	artl	Weighted Average Number Of Share Outstanding Basics And Diluted WeightedAverageNumberOfShareOutstandingBasicsAndDiluted	2230000	shares
CY2021	artl	Weighted Average Number Of Share Outstanding Basics And Diluted WeightedAverageNumberOfShareOutstandingBasicsAndDiluted	1245000	shares
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	3875000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8103000	usd
CY2021	artl	Common Shares Issued For Exercise Of Warrant Amount CommonSharesIssuedForExerciseOfWarrantAmount	6016000	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	34000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1531000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7437000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-46000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	12042000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	18262000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	934000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4035000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-36000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	27167000	usd
CY2022	artl	Common Shares Issued As Commitment Fee Amount CommonSharesIssuedAsCommitmentFeeAmount	97000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2458000	usd
CY2022	artl	Stock Issued During Period Shares Value Reverse Stock Splits StockIssuedDuringPeriodSharesValueReverseStockSplits	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10083000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-236000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	19403000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	10083000	usd
	us-gaap	Profit Loss ProfitLoss	4035000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	7437000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2458000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	934000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1531000	usd
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-207000	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-6000	usd
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	2000	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	39000	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	10000	usd
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense	7000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	195000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	63000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	239000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	507000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	33000	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-7000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-43000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-7000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8008000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2667000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6141000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	12725000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	11243000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	6098000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	499000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1524000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	15657000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2734000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2659000	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	525000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2958000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18262000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8103000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6016000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1000	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	8000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18261000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14112000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-224000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-28000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-45000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5274000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5533000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4487000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12162000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6629000	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2142000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6888000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12162000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6629000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	artl	Initial Recognition Of The Right Of Use Asset And Lease Liability InitialRecognitionOfTheRightOfUseAssetAndLeaseLiability	20000	usd
	artl	Initial Recognition Of The Right Of Use Asset And Lease Liability InitialRecognitionOfTheRightOfUseAssetAndLeaseLiability	0	usd
CY2021	artl	Initial Recognition Of The Right Of Use Asset And Lease Liability InitialRecognitionOfTheRightOfUseAssetAndLeaseLiability	97000	usd
CY2022	artl	Common Shares Issued As Commitment Fee CommonSharesIssuedAsCommitmentFee	97000	usd
	artl	Common Shares Issued As Commitment Fee CommonSharesIssuedAsCommitmentFee	0	usd
CY2021	artl	Common Shares Issued As Commitment Fee CommonSharesIssuedAsCommitmentFee	0	usd
CY2022	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	24000	usd
	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	5000	usd
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	0	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ARTELO BIOSCIENCES, INC. (“we”, “us”, “our”, the “Company”) is a Nevada corporation incorporated on May 2, 2011, and based in San Diego County, California. The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America, and the Company’s fiscal year end is December 31.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company registered fully owned subsidiaries in Ireland, Trinity Reliant Ventures Limited, on November 11, 2016, and in the UK, Trinity Research & Development Limited, on June 2, 2017. On January 8, 2020, Trinity Research and Development Limited changed its name to Artelo Biosciences Limited. The Company incorporated a wholly owned subsidiary in Canada, Artelo Biosciences Corporation, on March 18, 2020. Operations in the subsidiaries have been consolidated in the financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate the endocannabinoid system.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Liquidity</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has incurred losses since inception and incurred a net loss of $10,083 during the year ended December 31, 2022. However, in November 2021, the Company completed an equity offering which generated net proceeds of $18,262. Additionally, in May 2022, the Company entered into a purchase agreement and a registration rights agreement (the “Equity Line”) with an institutional investor, providing for the sale of up to $20,000 worth of the Company’s common stock, over the thirty-six (36) month term of the purchase agreement. Under the terms and subject to the conditions of the purchase agreement, the Company has the right, but not the obligation, to sell to the institutional investor, and the institutional investor is obligated to purchase, up to $20,000 worth of shares of the Company’s Common Stock. As of December 31, 2022, there have been no sales under the Equity Line. The Company’s existing cash resources and the cash received from the November 2021 equity offering are expected to provide sufficient funds to carry out the Company’s planned operations into the second half of 2024. To continue operations beyond such time frame, the Company will be required to raise additional funds by completing additional equity or debt offerings or licensing our product candidates. There can be no assurance that the Company will be successful in acquiring additional funding, that the Company’s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Reverse stock split</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 8, 2022, the Company, filed with the Secretary of State of the State of Nevada, a Certificate of Change, pursuant to Nevada Revised Statutes 78.209, to effect a one-for-fifteen (1-for-15) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding Common Stock, par value $0.001 per share. The Reverse Stock Split was effective as of August 10, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As a result of the Reverse Stock Split, the number of authorized shares of Common Stock has been reduced from 750,000,000 to 50,000,000, while the number of authorized shares of the Company’s preferred stock has been reduced from 6,250,000 to 416,667.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>COVID-19</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As the COVID-19 pandemic is still evolving at this time and much of its impact remains unknown, the Company is not able to predict the impact it may have on the development of its product candidates and business. The severity of the COVID-19 pandemic could also negatively impact the Company’s access to its existing supply chain by delaying the delivery of key raw materials used in its product candidates and therefore delay the delivery of such products for use in its clinical trials. Any of these results could have a material adverse impact to our business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All share and per share information in these financial statements retroactively reflect this Reverse Stock Split.</p>
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	18262000	usd
CY2022	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-15
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	6250000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	416667	shares
CY2022	us-gaap	Property Plant And Equipment Depreciation Methods PropertyPlantAndEquipmentDepreciationMethods	straight-line method
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	11951000	usd
CY2021Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	1519000	usd
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	13470000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</p>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6888000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12162000	usd
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q4	artl	Amount In Excess Of Fdic Insurance Amount AmountInExcessOfFdicInsuranceAmount	6388000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	9150000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11951000	usd
CY2021Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3436000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1495000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1519000	usd
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	9150000	usd
CY2022Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	1495000	usd
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	10645000	usd
CY2021Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	3436000	usd
CY2022	artl	Share Based Expenses ShareBasedExpenses	2458000	usd
	artl	Share Based Expenses ShareBasedExpenses	934000	usd
CY2021	artl	Share Based Expenses ShareBasedExpenses	1531000	usd
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	486184000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	416667	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	artl	Options Exercisable Description OptionsExercisableDescription	Lincoln Park of up to $20,000 worth of the Company’s Common Stock, over the thirty-six (36) month term of the Lincoln Park Agreements. The Company issued to Lincoln Park 19,532 shares of its Common Stock as commitment shares in consideration for entering into the Lincoln Park Agreements and received no funds in exchange for such commitment shares, valued at $97. Upon initiation of the Lincoln Park Agreements, the Company recorded $381 as an expense within general and administrative expenses
CY2022	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	1184959	shares
CY2022Q4	artl	Common Stock Average Price Per Share CommonStockAveragePricePerShare	15.90
CY2022	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	18262	usd
CY2022	artl	Number Of Purchase Common Stock Shares NumberOfPurchaseCommonStockShares	674667	integer
CY2022	artl	Number Of Warrant Granted NumberOfWarrantGranted	674667000	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	25000000	shares
CY2018Q3	artl	Options Exercisable Description OptionsExercisableDescription	Options may be exercisable (“vest”) immediately or in increments based on time and/or performance criteria as determined by the administrator. The term of any option may not exceed 10 years (five years for any incentive stock option granted to a 10% stockholder), and unless otherwise determined by the administrator, each option must terminate no later than three months after the termination of the optionee’s employment (one year in the event of death or disability). Subject to a few minor exceptions, options may not be transferred other than by will or by the laws of descent and distribution.
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	20559000	usd
CY2022Q4	artl	Deferred Tax Asset Operating Loss Carryforwards DeferredTaxAssetOperatingLossCarryforwards	4338000	usd
CY2021Q4	artl	Deferred Tax Asset Operating Loss Carryforwards DeferredTaxAssetOperatingLossCarryforwards	3343000	usd
CY2021Q3	artl	Deferred Tax Asset Operating Loss Carryforwards DeferredTaxAssetOperatingLossCarryforwards	3864000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4338000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3343000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3864000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2039000	usd
CY2022	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On April 19, 2022, the Company entered into a lease arrangement for office space with an annual rent of $13 (£11) and the term of the arrangement is from April 2022 through September 2023.
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5633000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3784000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	9417000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-9417000	usd
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	2000	usd
CY2021	us-gaap	Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1	8000	usd
CY2021	artl	Gain Loss From Change In Fair Value Of Derivative Liabilities GainLossFromChangeInFairValueOfDerivativeLiabilities	0	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	5000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-54000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-59000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9466000	usd
CY2021	artl	Earnings Per Share Basics And Diluted EarningsPerShareBasicsAndDiluted	-5.24
CY2021	artl	Weighted Average Number Of Share Outstanding Basics And Diluted WeightedAverageNumberOfShareOutstandingBasicsAndDiluted	1795000	shares

Files In Submission

Name	View Source	Status
0001640334-23-000509-index-headers.html	Edgar Link	pending
0001640334-23-000509-index.html	Edgar Link	pending
0001640334-23-000509.txt	Edgar Link	pending
0001640334-23-000509-xbrl.zip	Edgar Link	pending
artl-20221231.xsd	Edgar Link	pending
artl_10k.htm	Edgar Link	pending
artl_231.htm	Edgar Link	pending
artl_ex311.htm	Edgar Link	pending
artl_ex321.htm	Edgar Link	pending
artl_ex41.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
artl-20221231_cal.xml	Edgar Link	unprocessable
artl-20221231_pre.xml	Edgar Link	unprocessable
artl-20221231_def.xml	Edgar Link	unprocessable
artl-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
artl_10k_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARTL
ARTELO BIOSCIENCES, INC. Stock $artl

2023 Q1 Form 10-K Financial Statement

#000164033423000509 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTL ARTELO BIOSCIENCES, INC. Stock $artl

2023 Q1 Form 10-K Financial Statement

#000164033423000509 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTL
ARTELO BIOSCIENCES, INC. Stock $artl